Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Esophageal Squamous Cell Carcinoma
Related studies linked through entity extraction aliases.
Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
- Status
- RECRUITING
- Phase
- PHASE2
Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE3
A Phase II Study of CRT Combined With QL1706 in ESCC Patients
- Status
- RECRUITING
- Phase
- PHASE2
Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC
- Status
- UNKNOWN
- Phase
- PHASE2
A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
ctDNA-based MRD Assessment in Local Advanced Esophageal Carcinoma
- Status
- UNKNOWN
- Phase
- N/A
Two-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody
- Status
- RECRUITING
- Phase
- N/A
Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC
- Status
- UNKNOWN
- Phase
- PHASE1
S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Quantitative Analysis of 18F-FAPI Dynamic PET/CT for Accurate Differential Diagnosis of MLN of ESCC
- Status
- UNKNOWN
- Phase
- N/A
Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)
- Status
- RECRUITING
- Phase
- PHASE2